Myotubular myopathy, also called X-linked centronuclear myopathy (XL-CNM), is a severe
congenital disease targeted for therapeutic trials. To date, biomarkers to monitor disease …

Myostatin, a transforming growth factor–β family member, is a negative regulator of skeletal
muscle growth. To explore the therapeutic potential of targeting myostatin in settings of …

Myostatin is a highly conserved negative regulator of skeletal muscle growth. Loss of
functional myostatin in cattle, mice, sheep, dogs, and humans results in increased muscle …

Skeletal muscle is one of the leading frameworks of the musculo-skeletal system, which
works in synergy with the bones. Long skeletal muscles provide stability and mobility to the …

Myostatin, a member of the transforming growth factor-β superfamily, has been implicated in
the potent negative regulation of myogenesis in murine models. However, little is known …

Myostatin, a negative regulator of muscle growth, is considered a potential therapeutic agent
for individuals suffering from various muscle wasting and strength declining diseases …

Myostatin (Mstn) participates in the regulation of skeletal muscle size and has emerged as a
regulator of muscle metabolism. Here, we hypothesized that lack of myostatin profoundly …

Background Myostatin (MSTN) is a key negative regulator of muscle mass in humans and
animals, having direct and indirect influences on molecular regulators of atrophy and …

Myostatin is an extracellular cytokine mostly expressed in skeletal muscles and known to
play a crucial role in the negative regulation of muscle mass. Upon the binding to activin …

Gene-targeted therapies, such as adeno-associated viral vector (AAV)-mediated gene
therapy and cell-mediated therapy using myogenic stem cells, are hopeful molecular …